/
•
•
Will Sun Pharma ever be able to shake off its murky past?
A slap on the wrist from the regulator hasn’t really helped restore investors’ faith in a company dogged by multiple governance and ethical issues.
9 March, 2021•13 min
0
9 March, 2021•13 min
0
Getting your Trinity Audio player ready...
Why read this story?
Editor's note: Sun Pharmaceutical Industries Ltd, its owner Dilip Shanghvi and six board members are out of the doghouse. They’ve finally managed to shake off the regulatory overhang that’s haunted them for over two years now. In the second week of February, India’s fourth most valuable pharma company settled charges of poor governance standards and non-disclosure of related party transactions, among others, with the market regulator. The media, which had been giving the pharma company a hard time all this while, was much kinder this time around, with mere mentions of the Securities and Exchange Board of India settlement orders. A cumulative payment of Rs 2.92 crore, without admission or denial of guilt, was all it took to close the case triggered by whistleblower complaints of impropriety at the company. With the regulatory ordeal finally over, Sun Pharma’s public shareholders should be happy. Right? Not really. A quick look at the company’s share price tells us a very different story. From a high of Rs 643.50 on 11 February (the SEBI orders were passed after the markets closed), the stock saw a …
More in Business
Business
Emami’s Rs 500 crore D2C bet may not fix its growth problem
The FMCG major returns to acquisitions as growth stalls, but its uneven track record and structural challenges raise questions over whether the strategy can deliver
You may also like
Business
SEBI calls out Rajesh Exports, but the endgame is unclear
While the regulator’s interim order alleges massive irregularities, the long arc of unfinished probes, hearings and appeals makes closure distant.
Business
How India’s mutual funds are powering through a flat market
As growth in equities cools, asset managers are looking to embed themselves in payrolls, payments, and credit. This raises their influence, but also the stakes.
Business
IPO-bound NSE has big plans for commodities
With competition in the segment intensifying, the chief business development officer of India’s largest exchange unpacks the bourse’s strategy going forward.